19.14
1.59%
0.30
Handel nachbörslich:
19.00
-0.14
-0.73%
Contineum Therapeutics Inc Aktie (CTNM) Neueste Nachrichten
Contineum Therapeutics (NASDAQ:CTNM) Trading 5% Higher - Defense World
Driehaus Capital Management LLC Acquires Shares of 66,667 Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
Wall Street SWOT: Contineum Therapeutics stock rides wave of promising assets - Investing.com
(CTNM) Investment Analysis and Advice - Stock Traders Daily
Sandia Investment Management LP Takes $88,000 Position in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - Defense World
Contineum Therapeutics, Inc.'s Lock-Up Period Will End on October 2nd (NASDAQ:CTNM) - MarketBeat
Contineum Therapeutics, Inc.'s Lock-Up Period To End on October 2nd (NASDAQ:CTNM) - MarketBeat
CD Projekt (OTCMKTS:OTGLY) Shares Up 2.8% - Defense World
Contineum Therapeutics, Inc.’s Lock-Up Period To End on October 2nd (NASDAQ:CTNM) - Defense World
BW LPG (OTCMKTS:BWLLY) Stock Price Down 0.1% - Defense World
NET Power Inc. (NYSE:NPWR) Major Shareholder Sells $12,348.00 in Stock - Defense World
Direxion Daily MSFT Bull 2X Shares Announces Quarterly Dividend of $0.33 (NASDAQ:MSFU) - Defense World
Hilton Worldwide Holdings Inc. (NYSE:HLT) Shares Acquired by Xponance Inc. - Defense World
Blue Star Gold (CVE:BAU) Shares Down 9.1% - Defense World
Bank of Nova Scotia (TSE:BNS) Lifted to “Strong-Buy” at Cibc World Mkts - Defense World
Zacks Research Comments on Vail Resorts, Inc.’s FY2024 Earnings (NYSE:MTN) - Defense World
Mill Creek Capital Advisors LLC Makes New Investment in Vanguard High Dividend Yield ETF (NYSEARCA:VYM) - Defense World
Evergreen Capital Management LLC Acquires 519 Shares of BlackRock, Inc. (NYSE:BLK) - Defense World
Origin Enterprises (LON:OGN) Sets New 12-Month High After Dividend Announcement - Defense World
Q3 2024 Earnings Estimate for Biogen Inc. (NASDAQ:BIIB) Issued By Wedbush - Defense World
Kenvue (NYSE:KVUE) Downgraded by Royal Bank of Canada - Defense World
The US IPO Engine Looks Ready to Speed Ahead in Second Quarter - MSN
Contineum Therapeutics (NASDAQ:CTNM) Sees Strong Trading Volume - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Sees Large Volume Increase - MarketBeat
Breaking Biotech Barriers: Avidity President & CEO Sarah Boyce on RNA’s Next Frontier - Audacy
Applied Therapeutics, Inc. (NASDAQ:APLT) Receives Consensus Recommendation of “Buy” from Brokerages - Defense World
Amplify Alternative Harvest ETF (NYSEARCA:MJ) Shares Purchased by Commonwealth Equity Services LLC - Defense World
Truist downgrades Incyte to "hold" on doubts of near-term prospects - XM
Intercede locks in further contract orders and renewals - ShareCast
Chimera Investment Co. (NYSE:CIM) Shares Sold by Commonwealth Equity Services LLC - Defense World
Photos: INCUBUS & COHEED AND CAMBRIA At Madison Square Garden - Metal Injection
ICE NINE KILLS To Provide Official Song For TERRIFIER 3 Movie - bravewords.com
Official 'Terrifier 3' Music Video from Ice Nine Kills Slashing into Fantastic Fest & AMC Theatres! - Bloody Disgusting
Johnson & Johnson Buys Shares of 1,979,173 Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
(CTNM) Trading Advice - Stock Traders Daily
Behind Citius Pharmaceuticals Inc’s 52-Week Range: Uncovering Opportunities for Investors - The InvestChronicle
ICE NINE KILLS Announces New Song For Terrifier 3 - Metal Injection
Incyte CEO Hervé Hoppenot ‘motivated’ by move to downtown Wilmington - Technical.ly
Volkswagen AG (OTCMKTS:VWAPY) Sees Large Growth in Short Interest - Defense World
Versant Venture Management LLC Purchases New Stake in Contineum Therapeutics, Inc. (NASDAQ:CTNM) - MarketBeat
IPO class of 2024 shows value recovery despite mixed stock performance - BioWorld Online
Ionis announces proposed public offering of common stock - Quantisnow
Avidity Biosciences Joins Patient and Advocacy Communities in Raising Awareness During National Muscular Dystrophy Awareness Month - Quantisnow
EVP Research Swayze Eric acquired $425 worth of shares (11 units at $38.64), increasing direct ownership by 0.03% to 34,907 units (SEC Form 4) - Quantisnow
EVP CLO & General Counsel O'Neil Patrick R. acquired $9,506 worth of shares (246 units at $38.64), increasing direct ownership by 0.51% to 48,873 units (SEC Form 4) - Quantisnow
Biogen Announces Positive Topline Results from Study of Higher Dose Regimen of Nusinersen, Showing Significant Benefit in Treatment of SMA - Quantisnow
EVP, Chief Development Officer Geary Richard S sold $32,159 worth of shares (651 units at $49.40), decreasing direct ownership by 0.76% to 84,823 units (SEC Form 4) - Quantisnow
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences - Elk Valley Times
Contineum Therapeutics discloses crystalline compound of LPAR1 antagonists - BioWorld Online
(CTNM) Technical Pivots with Risk Controls - Stock Traders Daily
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences - StockTitan
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences - Manchestertimes
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences - Business Wire
Avidity Biosciences to Participate in Upcoming Investor Conferences - Quantisnow
Ionis to present at upcoming investor conferences - Quantisnow
Contineum Therapeutics to Present at Multiple Upcoming Investor Conferences - Yahoo Finance
Knust-Godwin Selects Continuum Powders for Advanced Ni718 Lifecycle Management Project: Case Study - Business Wire
Contineum Therapeutics (NASDAQ:CTNM) Shares Up 5.3% - Defense World
Contineum Therapeutics (NASDAQ:CTNM) Stock Price Up 5.3% - MarketBeat
Validea Motley Fool Strategy Daily Upgrade Report8/16/2024 - Nasdaq
Royal Bank of Canada Increases Contineum Therapeutics (NASDAQ:CTNM) Price Target to $32.00 - Defense World
Stifel backs Contineum Therapeutics stock with Buy rating, highlights LPA1 antagonist - Investing.com
Stifel backs Contineum Therapeutics stock with Buy rating, highlights LPA1 antagonist - Investing.com India
Contineum Therapeutics (NASDAQ:CTNM) Announces Earnings Results - Defense World
RBC Capital bullish on Contineum Therapeutics stock as key assets show promise - Investing.com
CTNM Stock Earnings: Contineum Therapeutics Misses EPS for Q2 2024 - MSN
Avidity Biosciences Announces Pricing of Upsized Public Offering of Common Stock - Quantisnow
Ethics & Equity: Youth-Specific Digital Therapeutics and the Continuum of Care - Child Mind Institute
Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $32.00 at Royal Bank of Canada - MarketBeat
Contineum Therapeutics (NASDAQ:CTNM) Issues Earnings Results - MarketBeat
RBC Capital bullish on Contineum Therapeutics stock as key assets show promise - Investing.com Australia
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Kapitalisierung:
|
Volumen (24h):